Gui‐Dong Zhu

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 773 citations · Full text

Medicine, Oncology, Pharmacology +15

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

Thomas D. Penning, Gui‐Dong Zhu, Viraj B. Gandhi et al. · Journal of Medicinal Chemistry · 2008 · 269 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

ABT-888 Confers Broad <i>In vivo</i> Activity in Combination with Temozolomide in Diverse Tumors

Joann P. Palma, Yichun Wang, Luis E. Rodrı́guez et al. · Clinical Cancer Research · 2009 · 139 citations

Medicine, Oncology, Pharmacology +16

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

Xuesong Liu, Edward K. Han, Mark G. Anderson et al. · Molecular Cancer Research · 2009 · 91 citations

Life Sciences, Molecular Biology, Oncology +16

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors

Keith W. Woods, John P. Fischer, Akiyo Claiborne et al. · Bioorganic & Medicinal Chemistry · 2006 · 81 citations

Pharmacy, Medicinal Chemistry, Pharmacology +9